The trading price of Pacific Biosciences of California Inc (NASDAQ:PACB) closed higher on Tuesday, March 04, and closing at $1.35, 2.66% higher than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $5.23 and a 52-week low of $1.16. Over the past month, the stock has lost -12.34% in value.
Pacific Biosciences of California Inc, whose market valuation is $369.72 million at the time of this writing, is expected to release its quarterly earnings report in April. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.19 per share this quarter, however they have predicted annual earnings per share of -0.73 for current year and -0.59 for next year.
Analysts have forecast the company to bring in revenue of 33.66M for the current quarter, with the likely lows of 31.29M and highs of 35.13M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 161.82M.
On the technical side, indicators suggest PACB has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 50% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned PACB a recommendation rating is 11. Out of them, 4 rate it a Hold, while 6 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Pacific Biosciences of California Inc (PACB) as Underweight, while 1 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that PACB’s price is currently -12.35% off the SMA20 and -20.55% off the SMA50. The RSI metric on the 14-day chart is currently showing 40.37, and weekly volatility stands at 10.92%. When measured over the past 30 days, the indicator reaches 13.01%. Pacific Biosciences of California Inc (NASDAQ:PACB)’s beta value is currently sitting at 2.01, while the Average True Range indicator is currently displaying 0.18. With analysts defining $2-$4 as the low and high price targets, we arrive at a consensus price target of $3 for the trailing 12-month period. The current price is about -48.15% off the estimated low and -196.3% off the forecast high, based on this estimate. Investors will be thrilled if PACB’s share price rises to $3, which is the median consensus price. At that level, PACB’s share price would be -122.22% below current price.
To see how Pacific Biosciences of California Inc stock has been performing in comparison to its peers in the industry, here are the numbers: PACB stock’s performance was 2.66% in the latest trading, and -75.59% in the past year. Another comparable company Standard BioTools Inc. (LAB) saw its stock close 4.95%% higher in the most recent trading session but was down -58.91% in a year.
An evaluation of the daily trading volume of Pacific Biosciences of California Inc (NASDAQ:PACB) indicates that the 3-month average is 11.33 million.
Currently, records show that 273.86 million of the company’s shares remain outstanding. The insiders hold 11.08% of outstanding shares, whereas institutions hold 84.36%. However, since the stock’s price has seen -26.23% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
